Skip to main content

Tenaya Therapeutics, Inc.

TNYA
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001858848

In the last 90 days, Tenaya Therapeutics, Inc. insiders filed 0 open-market purchases and 2 sales; 101 institutions reported holding it in 13F filings for Q2 2026, worth $39.7M in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Tenaya Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
2 filings
2 insiders, $21.0K in total
Insiders trading
2
Net value
−$21.0K
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Tenaya Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Tenaya Therapeutics, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Ali FarazChief Executive Officer539,782Sep 11, 20266
Tingley WhittemoreChief Medical Officer263,073Sep 11, 20266
Hyllengren Eric JChief Financial Officer–Jul 14, 20261
Williams R SandersDirector–May 29, 20261
Walsh Jeffrey T.Director–May 29, 20261
Parschauer Karah HerdmanDirector–May 29, 20261
Lee JuneDirector–May 29, 20261
Stehman-Breen CatherineDirector–May 29, 20261
Srivastava DeepakDirector372,435IndirectMay 29, 20261
Burroughs Amy L.Director–May 29, 20261
Higa TomohiroSVP, Finance118,267May 19, 20264
Svennilson Peter10% Owner0IndirectFeb 26, 20263
Kutzkey Tim10% Owner0IndirectFeb 26, 20263
Column Group III-A, LP10% Owner0IndirectFeb 26, 20263
Column Group III, LP10% Owner0IndirectFeb 26, 20263
Column Group III GP, LP10% Owner0IndirectFeb 26, 20263
Column Group Opportunity III, LP10% Owner0IndirectFeb 26, 20263
TCG Opportunity III GP, LLC10% Owner0IndirectFeb 26, 20263
Column Group Opportunity III GP, LP10% Owner0IndirectFeb 26, 20263
Goeddel David VDirector, 10% Owner49,313,559IndirectMay 30, 20250
Saito ChihiroSVP, Accounting and Fin. Ops.60,983Nov 18, 20240
Hoey TimothyChief Scientific Officer245,346Mar 6, 20240
Patterson Leone DChief Fin. and Bus. Officer95,755Feb 27, 20240
Chen Jin-LongDirector–Jun 12, 20230
Casdin Capital, LLCDirector6,078,860IndirectNov 25, 20220
Casdin EliDirector6,078,860IndirectNov 25, 20220
Casdin Partners Master Fund, L.P.10% Owner361,969IndirectAug 4, 20210
Casdin Private Growth Equity Fund, L.P.10% Owner361,969IndirectAug 4, 20210
Casdin Private Growth Equity Fund GP, LLC10% Owner361,969IndirectAug 4, 20210
Kang JeenJooDirector25,000Aug 4, 20210

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Feb 17, 2026 (view filing)Feb 17Same dayTingley WhittemoreChief Medical OfficerSSale−5.16K$0.64−$3.30K−2.3%218.6K after3 lots
Feb 17, 2026 (view filing)Feb 17Same dayAli FarazChief Executive OfficerSSale−14.9K$0.64−$9.51K−3.2%443.4K after3 lots
Feb 17, 2026 (view filing)Feb 17Same dayHiga TomohiroSVP, FinanceSSale−3.47K$0.64−$2.22K−2.8%119.8K after3 lots
Feb 24, 2026 (view filing)4:13 PM ETFeb 20-234 daysSvennilson Peter and 7 others10% OwnerSSale−829.7K$0.6084−$504.8K−27.3%2.21M after4 lots
Feb 26, 2026 (view filing)4:23 PM ETFeb 24-252 daysSvennilson Peter and 7 others10% OwnerSSale−4.17M$0.5708−$2.38M−100.0%0 after4 lots
May 19, 2026 (view filing)May 181 dayHiga TomohiroSVP, FinanceSSale−1.49K$0.79−$1.17K−1.2%118.3K after
May 19, 2026 (view filing)May 181 dayTingley WhittemoreChief Medical OfficerSSale−3.12K$0.79−$2.47K−1.4%215.5K after
May 19, 2026 (view filing)May 181 dayAli FarazChief Executive OfficerSSale−3.39K$0.79−$2.68K−0.8%440.0K after
Aug 17, 2026 (view filing)8:49 PM ETAug 17Same dayTingley WhittemoreChief Medical OfficerSSale−7.42K$0.7098−$5.27K−3.4%214.1K after4 lots
Aug 17, 2026 (view filing)8:50 PM ETAug 17Same dayAli FarazChief Executive OfficerSSale−22.2K$0.7097−$15.8K−5.1%417.8K after4 lots